Evidentic • Therapeutic Indications • Renal Cell Carcinoma (RCC)
Renal cell carcinoma (RCC), also called hypernephroma, renal adenocarcinoma or renal or kidney cancer, is the most common kind of kidney cancer found in adults. Kidneys have the function of taking out waste products from the body and produce urine. In this type of cancer, the malignant cells are found in the lining of tubules (very small tubes) in the kidney.
Showing 1–12 of 26 results
ProductBatch | Antigen | Molecular Class | Drug Brand | Product Concentration | CoA | Quantity per vial | Storage Temperature | Expiry Date | Price | |
---|---|---|---|---|---|---|---|---|---|---|
PD-L1 |
Monoclonal Antibody |
Bavencio® |
20 mg/mL |
– |
2 mg |
-80°C |
01/2021 |
236,00Â € |
||
VEGF-A |
Monoclonal Antibody |
Avastin® |
25 mg/mL |
– |
2 mg |
-80°C |
06/2018 |
238,00Â € |
||
VEGF-A |
Monoclonal Antibody |
Avastin® |
25 mg/mL |
– |
2 mg |
-80°C |
09/2018 |
238,00Â € |
||
VEGF-A |
Monoclonal Antibody |
Avastin® |
25 mg/mL |
– |
2 mg |
-80°C |
09/2018 |
238,00Â € |
||
VEGF-A |
Monoclonal Antibody |
Avastin® |
25 mg/mL |
– |
2 mg |
-80°C |
12/2018 |
238,00Â € |
||
VEGF-A |
Monoclonal Antibody |
Avastin® |
25 mg/mL |
– |
2 mg |
-80°C |
03/2019 |
238,00Â € |
||
VEGF-A |
Monoclonal Antibody |
Avastin® |
25 mg/mL |
– |
2 mg |
-80°C |
08/2019 |
238,00Â € |
||
VEGF-A |
Monoclonal Antibody |
Avastin® |
25 mg/mL |
– |
2 mg |
-80°C |
10/2019 |
238,00Â € |
||
VEGF-A |
Monoclonal Antibody |
Avastin® |
25 mg/mL |
yes |
2 mg |
-80°C |
03/2021 |
238,00Â € |
||
VEGF-A |
Monoclonal Antibody |
Avastin® |
25 mg/mL |
– |
3 mg |
-80°C |
09/2017 |
327,00Â € |
||
VEGF-A |
Monoclonal Antibody |
Avastin® |
25 mg/mL |
– |
3 mg |
-80°C |
03/2018 |
327,00Â € |
||
CTLA-4 |
Monoclonal Antibody |
Yervoy® |
5 mg/mL |
yes |
2 mg |
-80°C |
08/2021 |
952,00Â € |
||
PD-1 |
Monoclonal Antibody |
Opdivo® |
10 mg/mL |
– |
2 mg |
-80°C |
08/2018 |
270,00Â € |
||
PD-1 |
Monoclonal Antibody |
Opdivo® |
10 mg/mL |
– |
2 mg |
-80°C |
10/2018 |
270,00Â € |
||
PD-1 |
Monoclonal Antibody |
Opdivo® |
10 mg/mL |
– |
2 mg |
-80°C |
02/2018 |
270,00Â € |
||
PD-1 |
Monoclonal Antibody |
Opdivo® |
10 mg/mL |
– |
2 mg |
-80°C |
05/2019 |
270,00Â € |
||
PD-1 |
Monoclonal Antibody |
Opdivo® |
10 mg/mL |
– |
2 mg |
-80°C |
01/2019 |
270,00Â € |
||
PD-1 |
Monoclonal Antibody |
Opdivo® |
10 mg/mL |
– |
2 mg |
-80°C |
09/2020 |
270,00Â € |
||
PD-1 |
Monoclonal Antibody |
Opdivo® |
10 mg/mL |
– |
2 mg |
-80°C |
11/2020 |
270,00Â € |
||
PD-1 |
Monoclonal Antibody |
Opdivo® |
10 mg/mL |
– |
2 mg |
-80°C |
02/2021 |
270,00Â € |
||
PD-1 |
Monoclonal Antibody |
Opdivo® |
10 mg/mL |
– |
2mg |
-80°C |
01/2024 |
270,00Â € |
||
PD-1 |
Monoclonal Antibody |
Keytruda® |
25 mg/mL |
– |
2 mg |
-80°C |
07/2018 |
794,00Â € |
||
PD-1 |
Monoclonal Antibody |
Keytruda® |
25 mg/mL |
– |
2 mg |
-80°C |
12/2018 |
794,00Â € |
||
PD-1 |
Monoclonal Antibody |
Keytruda® |
25 mg/mL |
– |
2 mg |
-80°C |
03/2019 |
794,00Â € |
||
PD-1 |
Monoclonal Antibody |
Keytruda® |
25 mg/mL |
– |
2 mg |
-80°C |
07/2019 |
794,00Â € |
||
PD-1 |
Monoclonal Antibody |
Keytruda® |
25 mg/mL |
yes |
2 mg |
-80°C |
04/2022 |
841,00Â € |
Let us know about your inquiry details and we’ll contact you shortly.